+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Gliclazide Market by Drug Type, Formulation, Dosage Form, Packaging, Distribution Channel, Patient Age Group, End-User, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6016142
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Gliclazide Market grew from USD 13.72 billion in 2023 to USD 14.64 billion in 2024. It is expected to continue growing at a CAGR of 7.21%, reaching USD 22.35 billion by 2030.

Gliclazide is an oral hypoglycemic agent used predominantly in the management of type 2 diabetes, and its market scope and definition revolve around its application in improving glycemic control in diabetic patients. The necessity of gliclazide arises from the growing prevalence of diabetes, driven by lifestyle factors such as poor diet, sedentary lifestyle, and rising obesity rates. Its application mainly focuses on its role as a sulfonylurea class drug, which works by stimulating insulin secretion in response to meals, making it crucial for patients who require enhanced insulin response. The end-use scope primarily includes hospitals, clinics, and individual diabetes management programs, predominantly in regions with high diabetes incidence, like North America, Europe, and parts of Asia. Market growth is influenced by factors such as increasing diabetes awareness, advancements in drug formulations with controlled-release capabilities, and expanding healthcare infrastructures. Potential opportunities are emerging in developing nations with rising middle-class populations and in markets focusing on personalized medicine offering patient-specific treatment regimens. However, limitations persist, including the possible side effects like hypoglycemia and weight gain associated with sulfonylureas, along with the competition from newer classes of anti-diabetic drugs such as GLP-1 receptor agonists and SGLT2 inhibitors. The challenging factors also encompass stringent regulatory requirements and the varying pace of generic drug approvals. Innovation opportunities lie in creating combination therapies that involve gliclazide to enhance efficacy and reduce side effects, as well as in devising digital health solutions for better medication adherence tracking. The nature of the gliclazide market remains competitive yet ripe for innovation, driven by healthcare providers seeking cost-effective and efficient management options for diabetes, underscoring the need for continued research into synergistic treatment regimens and patient-centric approaches.

Understanding Market Dynamics in the Gliclazide Market

The Gliclazide Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing obese population coupled with unhealthy diets and sedentary lifestyles
    • Rising investments in healthcare infrastructure and medical facilities
  • Market Restraints
    • Availability of alternative treatments in the market
  • Market Opportunities
    • Rising investment in R&D and healthcare infrastructure development
    • Advancements in personalize diabetic medications
  • Market Challenges
    • Stringent regulatory environment leading to time-consuming approval process

Exploring Porter’s Five Forces for the Gliclazide Market

Porter’s Five Forces framework further strengthens the insights of the Gliclazide Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Gliclazide Market

External macro-environmental factors deeply influence the performance of the Gliclazide Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Gliclazide Market

The Gliclazide Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Gliclazide Market

The Gliclazide Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Gliclazide Market

The Gliclazide Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gliclazide Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., Biocon, Cipla, Dr. Reddy’s Laboratories, Kavya Pharma, Kreative Organics, Lexicare Pharma Private Limited, Lupin Pharmaceuticals, Mankind Pharma, MANUS AKTTEVA BIOPHARMA LLP, Sanify Healthcare, Shobha Life Sciences, Supra Chemicals, Torrent Pharmaceuticals, Wellona Pharma, and Zeelab Pharmacy Private Limited.

Market Segmentation & Coverage

This research report categorizes the Gliclazide Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Immediate Release Gliclazide
    • Modified Release Gliclazide
  • Formulation
    • Capsules
    • Tablets
  • Dosage Form
    • Combination Therapy
    • Monotherapy
  • Packaging
    • Blister Packs
    • Bottles
    • Pouches
  • Distribution Channel
    • Drug Stores
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • End-User
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Application
    • Blood Sugar Control
    • Cardiovascular Benefits
    • Insulin Sensitivity Improvement
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing obese population coupled with unhealthy diets and sedentary lifestyles
5.1.1.2. Rising investments in healthcare infrastructure and medical facilities
5.1.2. Restraints
5.1.2.1. Availability of alternative treatments in the market
5.1.3. Opportunities
5.1.3.1. Rising investment in R&D and healthcare infrastructure development
5.1.3.2. Advancements in personalize diabetic medications
5.1.4. Challenges
5.1.4.1. Stringent regulatory environment leading to time-consuming approval process
5.2. Market Segmentation Analysis
5.2.1. Drug type: Increasing adoption of modified release gliclazide due to more extended and consistent blood glucose control
5.2.2. End-User: Increasing adoption in hospitals due to rapid onset of action to manage acute cases effectively
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Gliclazide Market, by Drug Type
6.1. Introduction
6.2. Immediate Release Gliclazide
6.3. Modified Release Gliclazide
7. Gliclazide Market, by Formulation
7.1. Introduction
7.2. Capsules
7.3. Tablets
8. Gliclazide Market, by Dosage Form
8.1. Introduction
8.2. Combination Therapy
8.3. Monotherapy
9. Gliclazide Market, by Packaging
9.1. Introduction
9.2. Blister Packs
9.3. Bottles
9.4. Pouches
10. Gliclazide Market, by Distribution Channel
10.1. Introduction
10.2. Drug Stores
10.3. Hospital Pharmacies
10.4. Online Pharmacies
10.5. Retail Pharmacies
11. Gliclazide Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Gliclazide Market, by End-User
12.1. Introduction
12.2. Homecare
12.3. Hospitals
12.4. Specialty Clinics
13. Gliclazide Market, by Application
13.1. Introduction
13.2. Blood Sugar Control
13.3. Cardiovascular Benefits
13.4. Insulin Sensitivity Improvement
14. Americas Gliclazide Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Gliclazide Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Gliclazide Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2023
17.2. FPNV Positioning Matrix, 2023
17.3. Competitive Scenario Analysis
17.3.1. Endogenex secures eighty-eight million dollars in Series C funding to advance pivotal ReCET study for innovative type 2 diabetes treatment
17.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. GLICLAZIDE MARKET RESEARCH PROCESS
FIGURE 2. GLICLAZIDE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GLICLAZIDE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GLICLAZIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
FIGURE 17. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 19. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 21. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. GLICLAZIDE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. GLICLAZIDE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. GLICLAZIDE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GLICLAZIDE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GLICLAZIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLICLAZIDE MARKET DYNAMICS
TABLE 7. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GLICLAZIDE MARKET SIZE, BY IMMEDIATE RELEASE GLICLAZIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GLICLAZIDE MARKET SIZE, BY MODIFIED RELEASE GLICLAZIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GLICLAZIDE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GLICLAZIDE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GLICLAZIDE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GLICLAZIDE MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GLICLAZIDE MARKET SIZE, BY BLISTER PACKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GLICLAZIDE MARKET SIZE, BY BOTTLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GLICLAZIDE MARKET SIZE, BY POUCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GLICLAZIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GLICLAZIDE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GLICLAZIDE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GLICLAZIDE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GLICLAZIDE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GLICLAZIDE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GLICLAZIDE MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GLICLAZIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GLICLAZIDE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GLICLAZIDE MARKET SIZE, BY BLOOD SUGAR CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GLICLAZIDE MARKET SIZE, BY CARDIOVASCULAR BENEFITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GLICLAZIDE MARKET SIZE, BY INSULIN SENSITIVITY IMPROVEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 65. CANADA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 66. CANADA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. CANADA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. CANADA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. CANADA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 73. MEXICO GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 74. MEXICO GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. MEXICO GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. MEXICO GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. CHINA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. CHINA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 106. CHINA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. CHINA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 108. CHINA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. CHINA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. CHINA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. CHINA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. INDIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. INDIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 114. INDIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. INDIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 116. INDIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. INDIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. INDIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. INDIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. JAPAN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 129. JAPAN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. JAPAN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 131. JAPAN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 132. JAPAN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. JAPAN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. JAPAN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. JAPAN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. THAILAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. THAILAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 178. THAILAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 179. THAILAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 180. THAILAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. THAILAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. THAILAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. THAILAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 201. DENMARK GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. DENMARK GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 203. DENMARK GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 204. DENMARK GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 205. DENMARK GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. DENMARK GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. DENMARK GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. DENMARK GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. EGYPT GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. EGYPT GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 211. EGYPT GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 212. EGYPT GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 213. EGYPT GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. EGYPT GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. EGYPT GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. EGYPT GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. FINLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 220. FINLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 221. FINLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. FINLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. FINLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. FINLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. FRANCE GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. FRANCE GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 227. FRANCE GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. FRANCE GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 229. FRANCE GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. FRANCE GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. FRANCE GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. FRANCE GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. GERMANY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. GERMANY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 235. GERMANY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 236. GERMANY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 237. GERMANY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. GERMANY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. GERMANY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. GERMANY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. ITALY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. ITALY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 251. ITALY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 252. ITALY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 253. ITALY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. ITALY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. ITALY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. ITALY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 276. NORWAY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 277. NORWAY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. NORWAY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. NORWAY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 280. NORWAY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. POLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 282. POLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 283. POLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 284. POLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 285. POLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. POLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 287. POLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. POLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. QATAR GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 290. QATAR GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 291. QATAR GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 292. QATAR GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 293. QATAR GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. QATAR GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. QATAR GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. QATAR GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. SPAIN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 322. SPAIN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 323. SPAIN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 324. SPAIN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 325. SPAIN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. SPAIN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 327. SPAIN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 328. SPAIN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 330. SWEDEN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 331. SWEDEN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 337. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 338. SWITZERLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 339. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 343. SWITZERLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 344. SWITZERLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 345. TURKEY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 346. TURKEY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 347. TURKEY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 348. TURKEY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 349. TURKEY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 350. TURKEY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 351. TURKEY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 352. TURKEY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 353. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 354. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 355. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 356. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 357. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 358. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 359. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 360. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 361. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 362. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 363. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 364. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 365. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 366. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 367. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 368. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 369. GLICLAZIDE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 370. GLICLAZIDE MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Gliclazide Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Anant Pharmaceuticals Pvt. Ltd.
  • Apotex Inc.
  • Biocon
  • Cipla
  • Dr. Reddy’s Laboratories
  • Kavya Pharma
  • Kreative Organics
  • Lexicare Pharma Private Limited
  • Lupin Pharmaceuticals
  • Mankind Pharma
  • MANUS AKTTEVA BIOPHARMA LLP
  • Sanify Healthcare
  • Shobha Life Sciences
  • Supra Chemicals
  • Torrent Pharmaceuticals
  • Wellona Pharma
  • Zeelab Pharmacy Private Limited

Methodology

Loading
LOADING...

Table Information